The "2014 Asia Pacific Biotech Investment Forum", jointly organized by the leading venture capital fund in the life science sector, Diamond Biofund and Institute for Biotechnology and Medicine Industry, was launched on July 22, invited Li Bin, Managing Director, Asia Region Morgan Stanley, Michael Zeng, General Manager, Healthcare Group CITICPE, Dr. Alexander Ng, Associate Principal McKinsey & Co., Michelle Lin, Director, Consumer, Retail and Healthcare Investment Banking Credit Suisse and other investment experts to share their point of views on investment, attracting international funds into the vigorous development of Taiwan's biotechnology industry. The event also invited Been-Huang Chiang, Executive Yuan Officer of Executive Yuan and Wei-Cho Chen, Ph.D., Chairman of Institute for Biotechnology and Medicine Industry to deliver the welcome speech, and Winston Town, Vice President of Diamond BioFund Inc. to hold a panel discussion in the end.

"The developing pace of the biotech industry was very long and the risk was high, so the capital stability was very important." Been-Huang Chiang, Executive Yuan Officer of Executive Yuan said in his speech. The era of "biotechnology economy" has been quietly launched and is becoming a crucial trend in leading global development; biotechnology industry and national industrial development has been inseparable as well.

Although the development of biotechnology in Asia seems to be promising, the challenge was still ahead, "It was the price that bears the brunt." Dr. Alexander Ng, Associate Principal McKinsey & Co. pointed out that the price of drugs listed in Asia is often lower than Europe and the United States; therefore, if multinational pharmaceutical companies wanted to enter the market, they must reconsider the drug production cost in line with the Asian market. "If Taiwan and China CFDA approval could link more, it would be a great advantage in fact!" He also appealed to Taiwan government and enterprises should grasp the wave of international pharmaceutical companies in the Asia-Pacific region investment, so that Taiwan has a better international competition advantage.

"The Taiwan market was small and must go out for mergers, acquisitions or joint ventures." Michelle Lin, Director, Consumer, Retail and Healthcare Investment Banking Credit Suisse pointed out that in the first half of the year, the pharmaceutical industry mergers and acquisitions were the most and international pharmaceutical companies cash out the negative-growth/ non-core business one after another.